Model-based drug development: application of modeling and simulation in drug development

[1]  B. Shin,et al.  Preparation and in vivo characterization of dual release tablet containing sarpogrelate hydrochloride , 2018, Journal of Pharmaceutical Investigation.

[2]  Soyoung Shin,et al.  Model-based drug development: application of modeling and simulation in drug development , 2017, Journal of Pharmaceutical Investigation.

[3]  H. Holzhütter,et al.  A unifying mathematical model of lipid droplet metabolism reveals key molecular players in the development of hepatic steatosis , 2017, The FEBS journal.

[4]  R. Löbenberg,et al.  Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations , 2017, Journal of Pharmaceutical Investigation.

[5]  N. Modi.  Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation , 2017, The AAPS Journal.

[6]  Soyoung Shin,et al.  Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation. , 2017, Molecular pharmaceutics.

[7]  E. Oh,et al.  Rationale and strategies for formulation development of oral fixed dose combination drug products , 2016, Journal of Pharmaceutical Investigation.

[8]  CJ Musante,et al.  Quantitative Systems Pharmacology: A Case for Disease Models , 2016, Clinical pharmacology and therapeutics.

[9]  K. Śmietana,et al.  Trends in clinical success rates , 2016, Nature Reviews Drug Discovery.

[10]  R. Upton,et al.  Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug , 2016, Pharmaceutical Research.

[11]  S. Marshall,et al.  Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation , 2016, CPT: pharmacometrics & systems pharmacology.

[12]  F. Kesisoglou,et al.  Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate , 2015, The AAPS Journal.

[13]  Wei Xiao,et al.  Benefits of Model-based Drug Development: A Rigorous, Planned Case Study , 2015, Commun. Stat. Simul. Comput..

[14]  S. Nadaf,et al.  Design, development, in vitro and in vivo evaluation of multicomponent tablet formulation for enteral delivery of atorvastatin calcium and felodipine , 2015, Journal of Pharmaceutical Investigation.

[15]  Tarek A. Leil,et al.  Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development , 2014, Front. Pharmacol..

[16]  Diansong Zhou,et al.  Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents , 2014, Biopharmaceutics & drug disposition.

[17]  J. Riviere,et al.  The application of allometric scaling principles to predict pharmacokinetic parameters across species , 2014, Expert opinion on drug metabolism & toxicology.

[18]  K Kretsos,et al.  Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab , 2014, CPT: pharmacometrics & systems pharmacology.

[19]  Parisa Gazerani,et al.  A novel strategy , 2014 .

[20]  D. Aggarwal,et al.  Establishing postprandial bio-equivalency and IVIVC for generic metformin sustained release small sized tablets , 2014, Journal of Pharmaceutical Investigation.

[21]  M. Hegen,et al.  A Multiscale Model of Interleukin-6–Mediated Immune Regulation in Crohn's Disease and Its Application in Drug Discovery and Development , 2014, CPT: pharmacometrics & systems pharmacology.

[22]  A. Tolcher,et al.  Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist , 2013, Drug Metabolism and Disposition.

[23]  Shiew-Mei Huang,et al.  The utility of modeling and simulation in drug development and regulatory review. , 2013, Journal of pharmaceutical sciences.

[24]  Daniel C Kirouac,et al.  Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors , 2013, Science Signaling.

[25]  K Rowland-Yeo,et al.  Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development , 2013, CPT: pharmacometrics & systems pharmacology.

[26]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development , 2012, CPT: pharmacometrics & systems pharmacology.

[27]  J. Cardot,et al.  In vitro–In Vivo Correlations: Tricks and Traps , 2012, The AAPS Journal.

[28]  Jan Snoeys,et al.  From preclinical to human – prediction of oral absorption and drug–drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example , 2012, Biopharmaceutics & drug disposition.

[29]  R. Iyengar,et al.  Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. , 2012, Annual review of pharmacology and toxicology.

[30]  P. Lowe,et al.  From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics , 2011, The AAPS Journal.

[31]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[32]  L. Ford,et al.  Pharmacokinetic–pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age , 2010, Epilepsia.

[33]  Thierry Lavé,et al.  Prediction of Pharmacokinetic Profile of Valsartan in Humans Based on in vitro Uptake‐Transport Data , 2009, Chemistry & biodiversity.

[34]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[35]  Marc Pfister,et al.  Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development , 2008, The AAPS Journal.

[36]  DE Mager,et al.  Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.

[37]  Vikram Sinha,et al.  Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation , 2005, The AAPS Journal.

[38]  John Davis,et al.  Deconvolution Based Approach for Level A In Vivo-In Vitro Correlation Modelling: Statistical Considerations , 2005 .

[39]  Atul Mehta,et al.  Population pharmacokinetic model for daunorubicin and daunorubicinol coadministered with zosuquidar.3HCl (LY335979) , 2004, Cancer Chemotherapy and Pharmacology.

[40]  Thierry Lavé,et al.  Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. , 2003, Journal of pharmaceutical sciences.

[41]  B. Shin,et al.  Pharmacokinetic scaling of SJ‐8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species‐invariant time methods , 2003, Biopharmaceutics & drug disposition.

[42]  A. Dunne,et al.  In Vivo–In Vitro Correlation (IVIVC) Modeling Incorporating a Convolution Step , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[43]  Hartmut Derendorf,et al.  Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives , 1999, Pharmaceutical Research.

[44]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[45]  H J Clewell,et al.  A physiologically based pharmacokinetic model for retinoic acid and its metabolites. , 1997, Journal of the American Academy of Dermatology.

[46]  I Mahmood,et al.  Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. , 1996, Journal of pharmaceutical sciences.

[47]  J. Lin,et al.  Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[48]  N. Holford,et al.  Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events. , 1995, Journal of clinical psychopharmacology.

[49]  C. DeVane,et al.  Evaluation of population pharmacokinetics in therapeutic trials. IV. Application to postmarketing surveillance , 1993, Clinical pharmacology and therapy.

[50]  W. Ritschel,et al.  The allometric approach for interspecies scaling of pharmacokinetic parameters. , 1992, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.

[51]  R. Ings,et al.  Interspecies scaling and comparisons in drug development and toxicokinetics. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.

[52]  J. Mordenti,et al.  Man versus beast: pharmacokinetic scaling in mammals. , 1986, Journal of pharmaceutical sciences.

[53]  Harold Boxenbaum,et al.  Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics , 1982, Journal of Pharmacokinetics and Biopharmaceutics.

[54]  D. Cutler,et al.  Numerical deconvolution by least squares: Use of prescribed input functions , 1978, Journal of Pharmacokinetics and Biopharmaceutics.

[55]  John G. Wagner,et al.  Fundamentals of Clinical Pharmacokinetics , 1975 .

[56]  Robert L. Dedrick,et al.  Animal scale-up , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[57]  S. Riegelman,et al.  New method for calculating the intrinsic absorption rate of drugs. , 1968, Journal of pharmaceutical sciences.

[58]  J. Wagner,et al.  Per cent absorbed time plots derived from blood level and/or urinary excretion data. , 1963, Journal of pharmaceutical sciences.

[59]  A. J. Clark,et al.  The reaction between acetyl choline and muscle cells , 1926, The Journal of physiology.

[60]  Jelena Parojcić,et al.  Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. , 2009, Molecular pharmaceutics.

[61]  Melvin E. Andersen,et al.  Preclinical Development Handbook: ADME and Biopharmaceutical Properties , 2007 .

[62]  T. Lavé,et al.  A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics , 2006, Clinical pharmacokinetics.

[63]  Malcolm Rowland,et al.  Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). , 2004, AAPS pharmSci.

[64]  Hartmut Derendorf,et al.  Pharmacokinetic/pharmacodynamic studies in drug product development. , 2002, Journal of pharmaceutical sciences.